董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Miglino | 男 | Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2026-02-09 |
| Daniel E. Handley | 男 | Director | 66 | 7.99万美元 | 0.56 | 2026-02-09 |
| Gregory S. St. Clair | 男 | Director | 60 | 9.10万美元 | 0.58 | 2026-02-09 |
| Chuck Nuzum | 男 | Director and Chairman of the Board | 77 | 12.43万美元 | 0.64 | 2026-02-09 |
| Matthew J. Hawryluk | 男 | Director | 48 | 9.10万美元 | 0.49 | 2026-02-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh Blacher | 男 | Chief Financial Officer | 53 | 50.39万美元 | 0.65 | 2026-02-09 |
| Christopher Miglino | 男 | Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2026-02-09 |
董事简历
中英对照 | 中文 | 英文- Christopher Miglino
-
Christopher Miglino自2010年4月与他人共同创立Srax，Inc.以来，一直担任Srax，Inc.首席执行官兼Srax，Inc.董事会成员。2017年1月，他被任命为Srax公司总裁。他还于2010年4月至2014年11月担任Srax，Inc. Chief Financial Officer。Miglino先生在过去20年里一直在数字广告领域工作，并成功创办和出售了两家互联网公司。这两家公司都卖给了在纳斯达克上市的上市公司。他对技术和品牌之间的关系有详细的了解。Miglino先生以前曾担任EVmo, Inc.（fka YaYYo，Inc）【场外交易代码：Yayo 】的董事会成员，并在其薪酬委员会任职至2020年1月。Miglino先生还担任过BIGtoken，Inc.的董事会主席和临时首席执行官，BIGtoken，Inc.是SARX 【 OTC：BGTK 】的前多数股权子公司。
Christopher Miglino, since co-founding Srax, Inc. company in April 2010, has served as Srax, Inc. Chief Executive Officer and a member of Srax, Inc. board of directors. He was appointed President of Srax, Inc. company in January 2017. He also served as Srax, Inc. Chief Financial Officer from April 2010 until November 2014. Mr. Miglino has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly-traded companies on the NASDAQ. He has a detailed understanding of the relationship between technology and brands. Mr. Miglino previously served as a Board member for EVmo, Inc. (fka YaYYo, Inc) [OTC: YAYO] and served on their compensation committee until January 2020. Mr. Miglino also served as chairman of the Board and as interim chief executive officer of BIGtoken, Inc., a former majority owned subsidiary of SARX [OTC: BGTK]. - Christopher Miglino自2010年4月与他人共同创立Srax，Inc.以来，一直担任Srax，Inc.首席执行官兼Srax，Inc.董事会成员。2017年1月，他被任命为Srax公司总裁。他还于2010年4月至2014年11月担任Srax，Inc. Chief Financial Officer。Miglino先生在过去20年里一直在数字广告领域工作，并成功创办和出售了两家互联网公司。这两家公司都卖给了在纳斯达克上市的上市公司。他对技术和品牌之间的关系有详细的了解。Miglino先生以前曾担任EVmo, Inc.（fka YaYYo，Inc）【场外交易代码：Yayo 】的董事会成员，并在其薪酬委员会任职至2020年1月。Miglino先生还担任过BIGtoken，Inc.的董事会主席和临时首席执行官，BIGtoken，Inc.是SARX 【 OTC：BGTK 】的前多数股权子公司。
- Christopher Miglino, since co-founding Srax, Inc. company in April 2010, has served as Srax, Inc. Chief Executive Officer and a member of Srax, Inc. board of directors. He was appointed President of Srax, Inc. company in January 2017. He also served as Srax, Inc. Chief Financial Officer from April 2010 until November 2014. Mr. Miglino has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly-traded companies on the NASDAQ. He has a detailed understanding of the relationship between technology and brands. Mr. Miglino previously served as a Board member for EVmo, Inc. (fka YaYYo, Inc) [OTC: YAYO] and served on their compensation committee until January 2020. Mr. Miglino also served as chairman of the Board and as interim chief executive officer of BIGtoken, Inc., a former majority owned subsidiary of SARX [OTC: BGTK].
- Daniel E. Handley
-
DanielE.Handley M.S.博士于2020年2月19日被任命为董事会成员。他担任南加州健康科学大学（Southern California University of Health Sciences）的临床和转化基因组研究所的教授和董事。此前，他是the Clinical and Translational Genome Research Institute的首席科学官，这是佛罗里达州501C3非营利公司。期间，他也曾担任Florida Gulf Coast University的生物科学系的礼节性教员任命。他曾担任高级梦百合技术解决方案公司Life-Seq，LLC的首席科学官，宝洁公司的高级研究员，大卫格芬加州大学洛杉矶分校医学院的高级行政人员、研究员和实验室经理，以及作为国家遗传学研究所（National Genetics Institute）的创始生物技术发明家。他持有Johns Hopkins University的生物物理学学士学位、Carnegie Mellon University的逻辑和计算硕士学位、the University of Pittsburgh的人类遗传学博士学位。他在Magee-Women&8217；s Research Institute完成博士后培训，研究应用于胎儿和产妇健康的先进基因组技术。他是美国海军（the U.S.Navy）的授勋老兵，曾担任核推进教练和潜艇核反应堆操作员。
Daniel E. Handley was appointed to the Board on February 19, 2020. Since April 15, 2019, he serves as a Professor and Program Director of Human Genetics and Genomics Graduate Education at Southern California University of Health Sciences, a 501(3) educational non profit institution. Previoly, he was the Chief Scientific Officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non profit corporation. During that time, he also held a ctesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University. He previoly served as the Chief Scientific Officer for Advanced Healthcare Technology Solutions, Inc., Life Seq, LLC, as a senior researcher at the Procter & Gamble Co., a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine, and as a founding biotechnology inventor for the National Genetics Institute. He holds a B.A. in Biophysics from Johns Hopkins University, an M.S. in Logic and Computation from Carnegie Mellon University, a Ph.D. in Human Genetics from the University of Pittsburgh. He completed his post doctoral training at Magee Women's Research Institute researching advanced genomic technologies applied to fetal and maternal health. He is a veteran of the U.S. Navy, having served as a nuclear propulsion instructor and a submarine nuclear reactor operator. - DanielE.Handley M.S.博士于2020年2月19日被任命为董事会成员。他担任南加州健康科学大学（Southern California University of Health Sciences）的临床和转化基因组研究所的教授和董事。此前，他是the Clinical and Translational Genome Research Institute的首席科学官，这是佛罗里达州501C3非营利公司。期间，他也曾担任Florida Gulf Coast University的生物科学系的礼节性教员任命。他曾担任高级梦百合技术解决方案公司Life-Seq，LLC的首席科学官，宝洁公司的高级研究员，大卫格芬加州大学洛杉矶分校医学院的高级行政人员、研究员和实验室经理，以及作为国家遗传学研究所（National Genetics Institute）的创始生物技术发明家。他持有Johns Hopkins University的生物物理学学士学位、Carnegie Mellon University的逻辑和计算硕士学位、the University of Pittsburgh的人类遗传学博士学位。他在Magee-Women&8217；s Research Institute完成博士后培训，研究应用于胎儿和产妇健康的先进基因组技术。他是美国海军（the U.S.Navy）的授勋老兵，曾担任核推进教练和潜艇核反应堆操作员。
- Daniel E. Handley was appointed to the Board on February 19, 2020. Since April 15, 2019, he serves as a Professor and Program Director of Human Genetics and Genomics Graduate Education at Southern California University of Health Sciences, a 501(3) educational non profit institution. Previoly, he was the Chief Scientific Officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non profit corporation. During that time, he also held a ctesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University. He previoly served as the Chief Scientific Officer for Advanced Healthcare Technology Solutions, Inc., Life Seq, LLC, as a senior researcher at the Procter & Gamble Co., a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine, and as a founding biotechnology inventor for the National Genetics Institute. He holds a B.A. in Biophysics from Johns Hopkins University, an M.S. in Logic and Computation from Carnegie Mellon University, a Ph.D. in Human Genetics from the University of Pittsburgh. He completed his post doctoral training at Magee Women's Research Institute researching advanced genomic technologies applied to fetal and maternal health. He is a veteran of the U.S. Navy, having served as a nuclear propulsion instructor and a submarine nuclear reactor operator.
- Gregory S. St. Clair
-
Gregory S.St.Clair，Sr.于2020年7月9日被任命为董事会成员。他是Sunstone Consulting，LLC（一家梦百合咨询公司，自2002年以来为美国各地的梦百合供应商提供服务）的创始人和管理成员。St.Clair先生和他的团队经常寻求有关合规、报销和收入完整性问题的专家，他们不断待命，以协助客户通过对国家卫生系统的创造性解决方案来应对财务挑战。此前，St.Clair先生曾担任CGI、IMRGlobal和Orion Consulting的全国Vice President，并担任Coopers&Lybrand的全国董事。他持有宾夕法尼亚州亨廷顿Juniata College的会计和财务学士学位。
Gregory S. St. Clair was appointed to the Board on July 9, 2020. He is the Founder and Managing Member of SunStone Consulting, LLC, a healthcare consulting firm that has served healthcare providers throughout the United States since 2002. As frequently sought experts on issues related to compliance, reimbursement and revenue integrity, Mr. St. Clair and his team are constantly on call to assist clients as they address financial challenges through creative solutions to the nation's health systems. He is a nationally recognized expert by government regulators and health law attorneys regarding reimbursement and compliance matters. Previoly, Mr. St. Clair worked as a national vice president for CGI, ImrGlobal, and Orion Consulting and as national director for Coopers & Lybrand. He holds a B.S. in Accounting and Finance from Juniata College in Huntington, Pennsylvania. - Gregory S.St.Clair，Sr.于2020年7月9日被任命为董事会成员。他是Sunstone Consulting，LLC（一家梦百合咨询公司，自2002年以来为美国各地的梦百合供应商提供服务）的创始人和管理成员。St.Clair先生和他的团队经常寻求有关合规、报销和收入完整性问题的专家，他们不断待命，以协助客户通过对国家卫生系统的创造性解决方案来应对财务挑战。此前，St.Clair先生曾担任CGI、IMRGlobal和Orion Consulting的全国Vice President，并担任Coopers&Lybrand的全国董事。他持有宾夕法尼亚州亨廷顿Juniata College的会计和财务学士学位。
- Gregory S. St. Clair was appointed to the Board on July 9, 2020. He is the Founder and Managing Member of SunStone Consulting, LLC, a healthcare consulting firm that has served healthcare providers throughout the United States since 2002. As frequently sought experts on issues related to compliance, reimbursement and revenue integrity, Mr. St. Clair and his team are constantly on call to assist clients as they address financial challenges through creative solutions to the nation's health systems. He is a nationally recognized expert by government regulators and health law attorneys regarding reimbursement and compliance matters. Previoly, Mr. St. Clair worked as a national vice president for CGI, ImrGlobal, and Orion Consulting and as national director for Coopers & Lybrand. He holds a B.S. in Accounting and Finance from Juniata College in Huntington, Pennsylvania.
- Chuck Nuzum
-
Chuck Nuzum于2020年7月9日被任命为董事会成员。他拥有丰富的首席财务官经验，任职范围从私人初创企业到大型上市公司。Nuzum先生目前在项目基础上为McKesson，Biomarin，Autodesk和Squire Patton Boggs等公司提供财务咨询服务，这些公司是初创公司的导师，并在几家公司的董事会任职。此前，他曾担任The Tyburn Group（金融服务公司，为客户创建和交付预付工资和通用卡程序）的联席创始人兼首席财务官。在此之前的四年中，Nuzum先生担任Dey，L.P.的财务总监，该公司是Merck KGaA的大型制药制造子公司。在此之前，他是SVC Financial Services的联合创始人、执行Vice President和首席财务官，SVC Financial Services是该领域首批在Tiburon，Inc.整合用于全球分销、Vice President财务和管理的移动货币解决方案的公司之一，他是公共安全和司法信息系统的领导者，也是全球领先的电子商务葡萄酒拍卖公司Winebid.com的首席财务官。二十多年来，Nuzum先生是Loomis Fargo&Co.的首席财务官，这是一家著名的ATM系统、装甲车和其他安全服务的国际供应商。Nuzum先生是一名注册会计师，在西雅图华盛顿大学（University of Washington at Seattle）获得学士学位。
Chuck Nuzum was appointed to the Board on July 9, 2020. He has extensive experience as a CFO that ranges from private start ups to large publicly traded companies. Mr. Nuzum presently provides financial consulting services on a project basis to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs, a financial services company and a company employing advanced technology to construct affordable homes and mentors start up companies. Previoly he was co founder and CFO of the Tyburn Group, a financial services company that creates and delivers prepaid payroll and general purpose card programs for ctomers. For the f years prior, Mr. Nuzum served as the Controller of Dey, L.P., a large pharmaceutical manufacturing subsidiary of Merck KGaA. Prior to that he was co founder, Executive Vice President and CFO of SVC Financials Services, one of the first companies in the field to integrate a mobile money solution for global distribution, Vice President of Finance and Administration at Tiburon, Inc., a leader in public safety and jtice information systems, and CFO of Winebid.com the world's leading e commerce wine auction company. For more than two decades, Mr. Nuzum was CFO of Loomis Fargo & Co., the ll known international provider of ATM systems, armored cars and other security services. Mr. Nuzum, a Certified Public Accountant, earned his BA at the University of Washington at Seattle. - Chuck Nuzum于2020年7月9日被任命为董事会成员。他拥有丰富的首席财务官经验，任职范围从私人初创企业到大型上市公司。Nuzum先生目前在项目基础上为McKesson，Biomarin，Autodesk和Squire Patton Boggs等公司提供财务咨询服务，这些公司是初创公司的导师，并在几家公司的董事会任职。此前，他曾担任The Tyburn Group（金融服务公司，为客户创建和交付预付工资和通用卡程序）的联席创始人兼首席财务官。在此之前的四年中，Nuzum先生担任Dey，L.P.的财务总监，该公司是Merck KGaA的大型制药制造子公司。在此之前，他是SVC Financial Services的联合创始人、执行Vice President和首席财务官，SVC Financial Services是该领域首批在Tiburon，Inc.整合用于全球分销、Vice President财务和管理的移动货币解决方案的公司之一，他是公共安全和司法信息系统的领导者，也是全球领先的电子商务葡萄酒拍卖公司Winebid.com的首席财务官。二十多年来，Nuzum先生是Loomis Fargo&Co.的首席财务官，这是一家著名的ATM系统、装甲车和其他安全服务的国际供应商。Nuzum先生是一名注册会计师，在西雅图华盛顿大学（University of Washington at Seattle）获得学士学位。
- Chuck Nuzum was appointed to the Board on July 9, 2020. He has extensive experience as a CFO that ranges from private start ups to large publicly traded companies. Mr. Nuzum presently provides financial consulting services on a project basis to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs, a financial services company and a company employing advanced technology to construct affordable homes and mentors start up companies. Previoly he was co founder and CFO of the Tyburn Group, a financial services company that creates and delivers prepaid payroll and general purpose card programs for ctomers. For the f years prior, Mr. Nuzum served as the Controller of Dey, L.P., a large pharmaceutical manufacturing subsidiary of Merck KGaA. Prior to that he was co founder, Executive Vice President and CFO of SVC Financials Services, one of the first companies in the field to integrate a mobile money solution for global distribution, Vice President of Finance and Administration at Tiburon, Inc., a leader in public safety and jtice information systems, and CFO of Winebid.com the world's leading e commerce wine auction company. For more than two decades, Mr. Nuzum was CFO of Loomis Fargo & Co., the ll known international provider of ATM systems, armored cars and other security services. Mr. Nuzum, a Certified Public Accountant, earned his BA at the University of Washington at Seattle.
- Matthew J. Hawryluk
-
Matthew J. Hawryluk于2022年11月29日被任命为董事会成员。Hawryluk博士被任命为董事会二级董事。Hawryluk博士自2015年11月起担任Gritstone bio公司执行副总裁兼首席商务官。自2020年3月以来，Hawryluk博士一直担任PathAI，Inc.的顾问委员会成员。在Gritstone之前，2011年4月至2015年10月，Hawryluk博士在Foundation Medicine, Inc.担任越来越重要的职务，该公司当时是一家公开的分子诊断公司（后来被罗氏收购），最近担任公司和业务发展副总裁。在此之前，他曾在赛默飞世尔公司的多个部门担任业务开发、市场营销和产品管理职务。Hawryluk博士在圣母大学获得了学士学位，在匹兹堡大学医学院获得了细胞生物学和蛋白质生物化学博士学位，并在卡内基梅隆大学泰珀商学院获得了斯沃茨创业研究员的工商管理硕士学位。
Matthew J. Hawryluk was appointed to the Board on November 29, 2022. Dr. Hawryluk was appointed to the Board as a Class II director. Dr. Hawryluk currently serves as a Chief Biness Officer working with multiple companies. Dr. Hawryluk served as Chief Biness Officer of AIRNA Corporation from January 2025 to June 2025. Prior to AIRNA, Dr. Hawryluk served as Executive Vice President and Chief Biness Officer of Gritstone bio, Inc. from November 2015 to December 2024. Prior to Gritstone, from April 2011 to October 2015, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, Inc., then a public molecular diagnostics company (subsequently acquired by Roche), most recently serving as Vice President, Corporate and Biness Development. Previoly, he held roles in biness development, marketing, and product management across multiple divisions of Thermo Fisher Scientific, Inc. Dr. Hawryluk received a B.S. from the University of Notre Dame, a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine and an M.B.A. at Carnegie Mellon University's Tepper School of Biness as a Swartz Entrepreneurial Fellow. - Matthew J. Hawryluk于2022年11月29日被任命为董事会成员。Hawryluk博士被任命为董事会二级董事。Hawryluk博士自2015年11月起担任Gritstone bio公司执行副总裁兼首席商务官。自2020年3月以来，Hawryluk博士一直担任PathAI，Inc.的顾问委员会成员。在Gritstone之前，2011年4月至2015年10月，Hawryluk博士在Foundation Medicine, Inc.担任越来越重要的职务，该公司当时是一家公开的分子诊断公司（后来被罗氏收购），最近担任公司和业务发展副总裁。在此之前，他曾在赛默飞世尔公司的多个部门担任业务开发、市场营销和产品管理职务。Hawryluk博士在圣母大学获得了学士学位，在匹兹堡大学医学院获得了细胞生物学和蛋白质生物化学博士学位，并在卡内基梅隆大学泰珀商学院获得了斯沃茨创业研究员的工商管理硕士学位。
- Matthew J. Hawryluk was appointed to the Board on November 29, 2022. Dr. Hawryluk was appointed to the Board as a Class II director. Dr. Hawryluk currently serves as a Chief Biness Officer working with multiple companies. Dr. Hawryluk served as Chief Biness Officer of AIRNA Corporation from January 2025 to June 2025. Prior to AIRNA, Dr. Hawryluk served as Executive Vice President and Chief Biness Officer of Gritstone bio, Inc. from November 2015 to December 2024. Prior to Gritstone, from April 2011 to October 2015, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, Inc., then a public molecular diagnostics company (subsequently acquired by Roche), most recently serving as Vice President, Corporate and Biness Development. Previoly, he held roles in biness development, marketing, and product management across multiple divisions of Thermo Fisher Scientific, Inc. Dr. Hawryluk received a B.S. from the University of Notre Dame, a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine and an M.B.A. at Carnegie Mellon University's Tepper School of Biness as a Swartz Entrepreneurial Fellow.
高管简历
中英对照 | 中文 | 英文- Josh Blacher
Josh Blacher，公司首席财务官，自2015年1月起担任该职位。在此之前，Blacher于2014年10月加入公司担任企业开发高级主管。Blacher在生物技术相关业务开发、运营和投资领域有着14年多的经验，在资本市场领域有着14年多的经验。加入公司之前，Blacher从2008年到2011年担任Teva Innovative Ventures（Teva Pharmaceuticals的早期和中期发展阶段投资和营业执照）业务开发主管。任职期间，Blacher帮助建立并管理Teva在生物技术公司的200个股权投资组合，涵盖多领域发展阶段的公司，从预临床到阶段3项目以及多个疗法领域。之前，从1995年到2005年Blacher在Deutsche Asset Management担任投资组合经理职位；在Morgan Stanley担任股权研究职位；在Lehman Brothers的并购小组工作。Blacher于2001年获得Columbia Business School 金融工商管理硕士学位；1995年获得Yeshiva University经济学文学学士学位。
Josh Blacher has been the Chief Financial Officer of BullFrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee of Danforth Advisors since September 2022, where he has worked as a Chief Financial Officer in a consulting capacity for a number of life sciences companies as ll as Managing Partner of Columb Circle Capital LLC since Augt 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as ll as Axe Compute, among others. During his tenure at Columb Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columb Circle Capital, Mr. Blacher served as Chief Biness Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to Augt 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and an M.B.A. from Columbia Biness School.- Josh Blacher，公司首席财务官，自2015年1月起担任该职位。在此之前，Blacher于2014年10月加入公司担任企业开发高级主管。Blacher在生物技术相关业务开发、运营和投资领域有着14年多的经验，在资本市场领域有着14年多的经验。加入公司之前，Blacher从2008年到2011年担任Teva Innovative Ventures（Teva Pharmaceuticals的早期和中期发展阶段投资和营业执照）业务开发主管。任职期间，Blacher帮助建立并管理Teva在生物技术公司的200个股权投资组合，涵盖多领域发展阶段的公司，从预临床到阶段3项目以及多个疗法领域。之前，从1995年到2005年Blacher在Deutsche Asset Management担任投资组合经理职位；在Morgan Stanley担任股权研究职位；在Lehman Brothers的并购小组工作。Blacher于2001年获得Columbia Business School 金融工商管理硕士学位；1995年获得Yeshiva University经济学文学学士学位。
- Josh Blacher has been the Chief Financial Officer of BullFrog AI Holdings, Inc. since December 2024. Mr. Blacher has served as an employee of Danforth Advisors since September 2022, where he has worked as a Chief Financial Officer in a consulting capacity for a number of life sciences companies as ll as Managing Partner of Columb Circle Capital LLC since Augt 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of Predictive Oncology since September 2023 as ll as Axe Compute, among others. During his tenure at Columb Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columb Circle Capital, Mr. Blacher served as Chief Biness Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to Augt 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts from Yeshiva University and an M.B.A. from Columbia Biness School.
- Christopher Miglino
Christopher Miglino自2010年4月与他人共同创立Srax，Inc.以来，一直担任Srax，Inc.首席执行官兼Srax，Inc.董事会成员。2017年1月，他被任命为Srax公司总裁。他还于2010年4月至2014年11月担任Srax，Inc. Chief Financial Officer。Miglino先生在过去20年里一直在数字广告领域工作，并成功创办和出售了两家互联网公司。这两家公司都卖给了在纳斯达克上市的上市公司。他对技术和品牌之间的关系有详细的了解。Miglino先生以前曾担任EVmo, Inc.（fka YaYYo，Inc）【场外交易代码：Yayo 】的董事会成员，并在其薪酬委员会任职至2020年1月。Miglino先生还担任过BIGtoken，Inc.的董事会主席和临时首席执行官，BIGtoken，Inc.是SARX 【 OTC：BGTK 】的前多数股权子公司。
Christopher Miglino, since co-founding Srax, Inc. company in April 2010, has served as Srax, Inc. Chief Executive Officer and a member of Srax, Inc. board of directors. He was appointed President of Srax, Inc. company in January 2017. He also served as Srax, Inc. Chief Financial Officer from April 2010 until November 2014. Mr. Miglino has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly-traded companies on the NSDAQ. He has a detailed understanding of the relationship between technology and brands. Mr. Miglino previously served as a Board member for EVmo, Inc. (fka YaYYo, Inc) [OTC: YAYO] and served on their compensation committee until January 2020. Mr. Miglino also served as chairman of the Board and as interim chief executive officer of BIGtoken, Inc., a former majority owned subsidiary of SARX [OTC: BGTK].- Christopher Miglino自2010年4月与他人共同创立Srax，Inc.以来，一直担任Srax，Inc.首席执行官兼Srax，Inc.董事会成员。2017年1月，他被任命为Srax公司总裁。他还于2010年4月至2014年11月担任Srax，Inc. Chief Financial Officer。Miglino先生在过去20年里一直在数字广告领域工作，并成功创办和出售了两家互联网公司。这两家公司都卖给了在纳斯达克上市的上市公司。他对技术和品牌之间的关系有详细的了解。Miglino先生以前曾担任EVmo, Inc.（fka YaYYo，Inc）【场外交易代码：Yayo 】的董事会成员，并在其薪酬委员会任职至2020年1月。Miglino先生还担任过BIGtoken，Inc.的董事会主席和临时首席执行官，BIGtoken，Inc.是SARX 【 OTC：BGTK 】的前多数股权子公司。
- Christopher Miglino, since co-founding Srax, Inc. company in April 2010, has served as Srax, Inc. Chief Executive Officer and a member of Srax, Inc. board of directors. He was appointed President of Srax, Inc. company in January 2017. He also served as Srax, Inc. Chief Financial Officer from April 2010 until November 2014. Mr. Miglino has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly-traded companies on the NSDAQ. He has a detailed understanding of the relationship between technology and brands. Mr. Miglino previously served as a Board member for EVmo, Inc. (fka YaYYo, Inc) [OTC: YAYO] and served on their compensation committee until January 2020. Mr. Miglino also served as chairman of the Board and as interim chief executive officer of BIGtoken, Inc., a former majority owned subsidiary of SARX [OTC: BGTK].